PitchSend

argenx SE Investor Day Presentation Deck

Efgartigimod: Data Support Favorable Benefit to Risk Ratio 600+ subjects dosed 125+ patients on efgartigimod for over 12 months argenx 100 patients on efgartigimod for over 18 months Clinical proof-of-concept in four indications (MG, ITP, PV, CIDP) No evidence of dose-limiting toxicities in healthy volunteers or patients across trials Opportunity to dose efgartigimod to maximum PD effect 22

View entire presentation